Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease

8 Apr 2025

Abstract excerpt

BACKGROUND: Whether include high-sensitivity C-reactive protein (Hs-CRP) in diagnostic flow remains debatable during the updated definition to metabolic dysfunction-associated steatotic liver disease (MASLD) despite systemic inflammation contributes to the disease development and progression. We aimed to identify values of hs-CRP compared to other inflammatory markers derived from routine blood tests in MASLD....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver Disease and Transplantation
Share to Liver Disease Diagnosis and Treatment
Share to Nutrition and Health in Aging

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40200156
DOI: 10.1186/s12876-025-03778-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver diseasePMID 40200156Read ↗

Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.Semantic proximity Read ↗

A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitisSemantic proximity Read ↗

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Semantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read ↗

Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessmentSemantic proximity Read ↗

Steatosis Non-Invasive Tests Accurately Predict Metabolic Dysfunction-Associated Steatotic Liver Disease, While Fibrosis Non-Invasive Tests Fall Short: Validation in U.S. Adult PopulationSemantic proximity Read ↗

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read ↗

Profiling the genome and proteome of metabolic dysfunction-associated steatotic liver disease identifies potential therapeutic targetsSemantic proximity Read ↗

Molecular characterization of liver steatosis through circulating proteins, metabolites and lipidsSemantic proximity Read ↗

Unveiling the Burden of MASLD and Liver Fibrosis in India: Novel Insights from the Phenome India Study into fibrosis without MASLDSemantic proximity Read ↗

Elevated Serum Growth Differentiation Factor 15 and Decorin Predict the Fibrotic Progression of Metabolic Dysfunction Associated Steatotic Liver DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.